GLP-3 RT (Glucagon-Like Peptide-3, Research Type) is an experimental peptide belonging to the glucagon-like peptide family, primarily investigated for its potential role in metabolic and neuroendocrine regulation. Structurally related to incretin-based peptides, GLP-3 has been explored in preclinical settings to evaluate its effects on appetite control, glucose homeostasis, and possible interactions with the central nervous system.

In laboratory environments, GLP-3 RT is utilized in both in vitro and in vivo studies to better understand its mechanisms of action, including receptor binding affinity and metabolic stability. Early research suggests that peptides within this class may influence pathways associated with insulin secretion, peripheral glucose sensitivity, and neuronal signaling related to satiety.

Additionally, there is growing scientific interest in its potential neuroprotective properties and its role in modulating metabolic stress responses. However, it is important to emphasize that GLP-3 RT remains in the experimental stage and has not been approved for clinical use in humans.

Therefore, its application is strictly limited to research purposes, and further controlled studies are required to establish its safety, efficacy, and pharmacokinetic profile.